Literature DB >> 34808635

Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Analysis from the Acute Coronary Syndrome Israeli Survey.

Ran Eliaz1, Bethlehem Mengesha2,3, Tal Ovdat4, Zaza Iakobishvili3,5, David Hasdai3,6, Mark Kheifets3,6, Robert Klempfner3,4,7, Roy Beigel3,7, Eran Kalmanovich2,3, Ronny Alcalai1, Amos Levi3,6.   

Abstract

INTRODUCTION: We aimed to compare the outcomes of acute coronary syndrome (ACS) patients undergoing in-hospital percutaneous coronary intervention treated with prasugrel versus ticagrelor.
METHODS: Among 7,233 patients enrolled to the Acute Coronary Syndrome Israeli Survey (ACSIS) between 2010 and 2018, we identified 1,126 eligible patients treated with prasugrel and 817 with ticagrelor. Comparison between the groups was performed separately in ST-elevation myocardial infarction (STEMI) patients, propensity score matched (PSM) STEMI patients, and non-ST-elevation ACS (NSTE-ACS) patients.
RESULTS: In-hospital complication rates, including rates of stent thrombosis, were not significantly different between groups. In PSM STEMI patients, 30-day re-hospitalization rate (p < 0.05), 30-day MACE (the composite of death, MI, stroke, and urgent revascularization, p = 0.006), and 1-year mortality rates (p = 0.08) were higher in the ticagrelor group compared to the prasugrel group; in NSTE-ACS patients, outcomes were not associated with drug choice. In Cox regression analysis applied on the entire cohort, prasugrel was associated with lower 1-year mortality in STEMI patients but not in NSTE-ACS patients (p for interaction 0.03).
CONCLUSIONS: Compared to ticagrelor, prasugrel was associated with superior clinical outcomes in STEMI patients, but not in NSTE-ACS patients.
© 2021 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Acute coronary syndrome; Percutaneous coronary intervention; Prasugrel; Ticagrelor

Mesh:

Substances:

Year:  2021        PMID: 34808635      PMCID: PMC9153328          DOI: 10.1159/000521042

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   2.342


  20 in total

1.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Patrick T O'Gara; Frederick G Kushner; Deborah D Ascheim; Donald E Casey; Mina K Chung; James A de Lemos; Steven M Ettinger; James C Fang; Francis M Fesmire; Barry A Franklin; Christopher B Granger; Harlan M Krumholz; Jane A Linderbaum; David A Morrow; L Kristin Newby; Joseph P Ornato; Narith Ou; Martha J Radford; Jacqueline E Tamis-Holland; Carl L Tommaso; Cynthia M Tracy; Y Joseph Woo; David X Zhao
Journal:  J Am Coll Cardiol       Date:  2012-12-17       Impact factor: 24.094

2.  Association of different antiplatelet therapies with mortality after primary percutaneous coronary intervention.

Authors:  Ivan Olier; Alex Sirker; David J R Hildick-Smith; Tim Kinnaird; Peter Ludman; Mark A de Belder; Andreas Baumbach; Jonathan Byrne; Muhammad Rashid; Nick Curzen; Mamas A Mamas
Journal:  Heart       Date:  2018-02-02       Impact factor: 5.994

3.  Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial.

Authors:  Han Saem Jeong; Soon Jun Hong; Sang-A Cho; Jong-Ho Kim; Jae Young Cho; Seung Hun Lee; Hyung Joon Joo; Jae Hyoung Park; Cheol Woong Yu; Do-Sun Lim
Journal:  JACC Cardiovasc Interv       Date:  2017-08-28       Impact factor: 11.195

4.  Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Authors:  Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman
Journal:  N Engl J Med       Date:  2007-11-04       Impact factor: 91.245

5.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

Authors:  Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

6.  Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.

Authors:  Matthew T Roe; Paul W Armstrong; Keith A A Fox; Harvey D White; Dorairaj Prabhakaran; Shaun G Goodman; Jan H Cornel; Deepak L Bhatt; Peter Clemmensen; Felipe Martinez; Diego Ardissino; Jose C Nicolau; William E Boden; Paul A Gurbel; Witold Ruzyllo; Anthony J Dalby; Darren K McGuire; Jose L Leiva-Pons; Alexander Parkhomenko; Shmuel Gottlieb; Gracita O Topacio; Christian Hamm; Gregory Pavlides; Assen R Goudev; Ali Oto; Chuen-Den Tseng; Bela Merkely; Vladimir Gasparovic; Ramon Corbalan; Mircea Cinteză; R Craig McLendon; Kenneth J Winters; Eileen B Brown; Yuliya Lokhnygina; Philip E Aylward; Kurt Huber; Judith S Hochman; E Magnus Ohman
Journal:  N Engl J Med       Date:  2012-08-25       Impact factor: 91.245

7.  Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With ST-Segment-Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Long-Term Follow-Up of the REDUCE-MVI Trial.

Authors:  Nina W van der Hoeven; Gladys N Janssens; Henk Everaars; Alexander Nap; Jorrit S Lemkes; Guus A de Waard; Peter M van de Ven; Albert C van Rossum; Javier Escaned; Hernan Mejia-Renteria; Tim J F Ten Cate; Jan J Piek; Clemens von Birgelen; Marco Valgimigli; Roberto Diletti; Niels P Riksen; Nicolas M Van Mieghem; Robin Nijveldt; Maarten A H van Leeuwen; Niels van Royen
Journal:  J Am Heart Assoc       Date:  2020-03-03       Impact factor: 5.501

8.  Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention.

Authors:  Arvindra Krishnamurthy; Claire Keeble; Michelle Anderson; Kathryn Somers; Natalie Burton-Wood; Charlotte Harland; Paul Baxter; Jim McLenachan; Jonathan Blaxill; Daniel J Blackman; Christopher Malkin; Stephen Wheatcroft; John Greenwood
Journal:  Open Heart       Date:  2019-06-29

9.  Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Authors:  Alp Aytekin; Gjin Ndrepepa; Franz-Josef Neumann; Maurizio Menichelli; Katharina Mayer; Jochen Wöhrle; Isabell Bernlochner; Shqipdona Lahu; Gert Richardt; Bernhard Witzenbichler; Dirk Sibbing; Salvatore Cassese; Dominick J Angiolillo; Christian Valina; Sebastian Kufner; Christoph Liebetrau; Christian W Hamm; Erion Xhepa; Alexander Hapfelmeier; Hendrik B Sager; Isabel Wustrow; Michael Joner; Dietmar Trenk; Massimiliano Fusaro; Karl-Ludwig Laugwitz; Heribert Schunkert; Stefanie Schüpke; Adnan Kastrati
Journal:  Circulation       Date:  2020-10-29       Impact factor: 29.690

10.  Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials.

Authors:  Eliano P Navarese; Safi U Khan; Michalina Kołodziejczak; Jacek Kubica; Sergio Buccheri; Christopher P Cannon; Paul A Gurbel; Stefano De Servi; Andrzej Budaj; Antonio Bartorelli; Daniela Trabattoni; E Magnus Ohman; Lars Wallentin; Matthew T Roe; Stefan James
Journal:  Circulation       Date:  2020-05-29       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.